Trial of Antiamyloid Agent in Prodromal Alzheimer's Halted
Medscape NeurologyHeadlines
The decision to halt the phase 3 trial of gantenerumab was based on a preplanned futility analysis, but the DIAN-TU trial, studying the agent in volunteers with an AD risk mutation, will continue.
Medscape Medical News
Original Article: http://www.medscape.com/viewarticle/837202?src=rss
No comments:
Post a Comment